Genor Biopharma Holdings (HKSE:06998) Growth Rank : 0 (As of Jan. 18, 2025)

View and export this data going back to 2020. Start your Free Trial

What is Genor Biopharma Holdings Growth Rank?

Genor Biopharma Holdings has the Growth Rank of 0.

GuruFocus Growth Rank measures the growth of a company in terms of its revenue and profitability. Historically, the companies with the highest growth ranks performed the best over the long term. It is calculated using the following criteria:

1. 5-year revenue growth rate, the higher, the better.
2. 3-year revenue growth rate, the higher, the better.
3. 5-year EBITDA growth rate, the higher, the better.
4. The predictability of 5-year revenue. The most consistent it is, the higher the rank.

GuruFocus found that the Growth Rank is the second of the two most-sensitive parameters among the five parameters checked. Please click GF Score to see more details on GF Score's 5 Key Aspects of Analysis.

Please note that we are using the five-year EBITDA growth rate as a parameter, so the company needs to have had positive growth over that time. The reason we use EBITDA instead of earnings per share is that with EBITDA, we can rank a lot more companies since a company may have positive EBITDA but negative EPS. Since we are looking at the growth here, EBITDA gives us a pretty clear picture about the growth in the company's business operations.

Genor Biopharma Holdings Growth Rank Related Terms

Thank you for viewing the detailed overview of Genor Biopharma Holdings's Growth Rank provided by GuruFocus.com. Please click on the following links to see related term pages.

Genor Biopharma Holdings Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Genor Biopharma Holdings Ltd (HKSE:06998) » Definitions » Growth Rank

Comparable Companies

Traded in Other Exchanges

67N0:Germany

Address

690 Bibo Road, Room 401-17, Building 6, Pudong New District, Shanghai, CHN, 201203

Website

https://www.genorbio.com

Genor Biopharma Holdings Ltd is a commercial-ready biopharmaceutical company focusing on developing and commercializing oncology and autoimmune drugs. The company is focused on therapeutic areas with substantial unmet medical needs in oncology, autoimmune, and other chronic diseases. Its key drug candidates include GB491 (lerociclib), a differentiated oral CDK4/6 inhibitor; GB221, a novel HER2 mAb drug candidate; geptanolimab (GB226), GB492, a STING agonist expected to exert synergistic effects in combination with GB226; GB242, an infliximab (Remicade) biosimilar; and GB223, a RANKL, and others.

Executives

Hillhouse Investment Management, Ltd.	2102 Investment manager
Hhjh Holdings Limited	2101 Beneficial owner
Hillhouse Fund Iv, L.p.	2201 Interest of corporation controlled by you
Hh Bio Investment Fund, L.p.	2201 Interest of corporation controlled by you
Hillhouse Capital Management, Ltd.	2102 Investment manager
Hh Bio Investment Fund L.p.	2201 Interest of corporation controlled by you
Temasek Capital (private) Limited
Aranda Investments Pte. Ltd.
Seletar Investments Pte Ltd
Walga Biotechnology Limited	2101 Beneficial owner
Shang Hai Wo Jia Sheng Wu Ji Shu You Xian Gong Si	2201 Interest of corporation controlled by you
Yun Nan Wo Sen Sheng Wu Ji Shu Gu Fen You Xian Gong Si	2201 Interest of corporation controlled by you
Temasek Holdings (private) Limited

Genor Biopharma Holdings Headlines

No Headlines